poisar

Stocks · News reference

BioVie Presents New Biomarker Data From ADDRESS-LC Trial Of Bezisterim In Long COVID; Analyses Suggest Single Efficacy Endpoint May Not Adequately Capture Clinically Meaningful Response To Therapeutic Intervention Across Biological Diversity Of Long Covid

BenzingaBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    BioVie Reports 3Q 2026 Financial Results

    BioVie Inc. reported its third-quarter 2026 financial results, noting a wider quarterly loss driven by increased research and development expenses for its Long COVID program.